Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Lantern Pharma Q4 2025 Earnings Call - Clinical validation across multiple programs and AI commercialization, but cash runway only into mid‑late 2026
Lantern Pharma used the Q4 2025 call to argue it has moved from hypothesis to clinic. Management highlighted clinical validation across multiple programs: meaningful signals in the LP-300 Harmonic tri...
- Company reports clinical validation across multiple programs: LP-300 Harmonic observations, completed LP-184 Phase I, and an FDA IND cleared for Starlight Therapeutics' pediatric CNS STAR-001 program; management says over 100 patients dosed across programs.
- LP-300 Harmonic trial targets never-smoker NSCLC post-TKI patients; initial safety lead-in showed an 86% clinical benefit rate and 43% objective response rate, including one durable complete response.
- Lantern submitted a Type C meeting package to FDA for LP-300, with the meeting scheduled mid-May 2026, seeking three protocol amendments: focus enrollment on EGFR exon 21 L858R patients, increase maximum cycles from six to eight, and convert to a single-arm Simon’s two-stage design.
- +11 more takeaways
Standard Lithium Ltd. Fourth Quarter 2025 Earnings Call - SWA DFS Clears Path to 2026 FID with Trafigura Offtake and ECA Debt Interest
Standard Lithium used the quarter to tidy up the prerequisites for a final investment decision at its Southwest Arkansas, or SWA, project. The company filed a positive definitive feasibility study for...
- Company filed a positive definitive feasibility study, DFS, for the Southwest Arkansas, or SWA, project showing an initial phase nameplate capacity of 22,500 metric tons per year of battery quality lithium carbonate.
- Smackover Lithium JV filed a maiden inferred resource report for the Franklin Project in East Texas, with management calling it among the highest reported brine lithium grades in North America.
- Standard Lithium received final regulatory approval from the Arkansas Oil and Gas Commission for integration of the Reynolds Brine unit, the planned site for the initial SWA phase.
- +15 more takeaways
Off The Hook Yachts Q4 and Full Year 2025 Earnings Call - $60M Floor Plan and Apex Acquisition to Accelerate Inventory Velocity and Raise 2026 Guidance
Off The Hook reported a strong 2025 marked by record revenue of $119.9 million, 426 boats sold, and an IPO in November that materially strengthened liquidity. Management is betting growth will come fr...
- Record 2025 revenue of $119.9 million, up 21.1% year over year.
- Unit volume hit a record 426 boats, up more than 32% from 2024.
- Company sold 240 company-owned inventory units and transacted 186 brokered deals in 2025.
- +14 more takeaways
Sangamo Therapeutics Q4 2025 Earnings Call - Rolling BLA for ST-920 After Positive STAR Results, Fabry Partnership and Cash Runway Now Central
Sangamo entered 2026 with its lead Fabry program driving the company narrative. Positive registrational STAR results and FDA confirmation that a one-year eGFR slope could support accelerated approval ...
- Sangamo reported positive top-line registrational STAR results for ST-920 in Fabry disease, including a positive mean annualized eGFR slope at 52 weeks across dosed patients, and at two years for 19 patients.
- The FDA reiterated in October 2025 that a one-year eGFR slope could serve as the primary basis for accelerated approval of ST-920, and Sangamo is pursuing that pathway.
- A rolling BLA submission for ST-920 is in progress, with the clinical and nonclinical modules already submitted to the FDA.
- +11 more takeaways
HireQuest, Inc. Fourth Quarter and Year-End 2025 Earnings Call - Divests MRI Permanent Placement, Retains Contract Staffing and Minority Stake
HireQuest reported a down-but-stable 2025, with revenues and system-wide sales sliding from 2024 while adjusted profitability held roughly steady. Management moved decisively on MRI Network, carving o...
- MRI restructuring is the call’s headline action: HireQuest divested the permanent placement/executive search portion of MRI into a new entity led by current and former franchise owners, effective January 1, 2026.
- Post-transaction, HireQuest retains full ownership of MRI’s contract staffing business, and maintains a minority ownership stake plus shared services support for the new MRI entity.
- CFO said the executive search arm generated roughly $65 million of system-wide sales in 2025 and just under $2 million in royalties, and was effectively break-even on an operating basis.
- +13 more takeaways
Spruce Power Fourth Quarter 2025 Earnings Call - Breakout year: margins widened, cash flow turned positive, refinancing now the critical next step
Spruce closed 2025 with a genuine operational inflection. Q4 revenue rose to about $24 million, operating EBITDA topped $17 million, and full year operating EBITDA hit $80.1 million, a 49% jump versus...
- Q4 2025 revenue approximately $24 million, up 19% year over year; full year revenue up 36% versus 2024.
- Q4 operating EBITDA exceeded $17 million; full year operating EBITDA was $80.1 million, a 49% increase year over year.
- Adjusted cash flow from operations swung to $5.1 million in Q4, versus -$4.1 million in Q4 2024, signaling improved cash generation.
- +11 more takeaways
INmune Bio Q4 2025 Earnings Call - CORDStrom on track for U.K. MAA mid-2026, BLA targeted end-2026
INmune Bio presented a bifurcated quarter: a regulatory push for CORDStrom while reconciling mixed readouts from its Alzheimer program. Management says CORDStrom has reproducible, pooled-donor manufac...
- CORDStrom is the companys lead value driver, positioned for registration in RDEB with an MAA planned in the U.K. by mid-summer 2026.
- Following the U.K. filing, INmune plans to submit an MAA to the EMA and a BLA to the FDA by the end of 2026, with regulatory feedback or approvals expected in 2027.
- Manufacturing claim: CORDStrom uses pooled mesenchymal stromal cell banks from four or more donors, delivering batch-to-batch consistency and reproducibility for commercial supply.
- +11 more takeaways
Intellinetics Q4 2025 Earnings Call - SaaS growth cushions services slump, investments weigh on profitability
Intellinetics closed 2025 with clear progress in SaaS, but not yet with a clean bill of health. SaaS revenue grew double digits for the year and was up 8.4% in Q4, improving margins and offsetting a m...
- CEO change: Alison Forsythe became CEO in mid-February and focused immediately on operations, go-to-market, and execution improvements.
- Q4 revenue: Total revenue for Q4 2025 was $4.3 million, up 1% year over year.
- SaaS growth: SaaS and hosting revenue rose 8.4% year over year in Q4 to $1.6 million; SaaS grew 11.1% for the full year.
- +11 more takeaways
Fermi America Q4 & FY 2025 Earnings Call - Matador substantially built, now hostage to tenant leases and project financing
Fermi America is no longer a paper promise, it is a construction site. Management reports roughly $570 million deployed into Project Matador, $935 million of PP&E in construction in progress, and key ...
- Project Matador has moved from formation to heavy construction: ~$570 million of investor capital deployed into Matador (construction in progress), PP&E of ~$935 million as of 12/31/2025.
- Company is pre-revenue. Net loss for the fiscal period was $486 million, with ~$445 million non-cash items; operating cash use was $34 million for the year.
- Cash and liquidity: $409 million cash on 12/31/2025, plus ~ $1 billion of financing proceeds in 2025 and subsequent equipment facilities (MUFG $500m turbine warehouse, Keystone $120m expandable, Yellowstone $165m) that, with cash, provide at least 12 months of liquidity.
- +11 more takeaways
PAVmed Fourth Quarter 2025 Earnings Call - Capital Structure Cleaned, Lucid Momentum and Medtech Relaunch Set the Agenda
PAVmed says the long, painful chapter of toxic convertibles is over. A February recapitalization and financing left the company with a clean cap table, roughly $30 million of new equity, $15 million o...
- Recapitalization completed in February removed legacy toxic convertible securities and produced a clean cap table, converting $30 million of short-term preferred into common and adding $15 million of 3-year, 15% interest-only debt.
- PAVmed now shows pro forma total assets north of $100 million after the financing, with $15 million of long-term debt on the balance sheet and a $30 million warrant package tied to the Series D.
- PAVmed remains the single largest shareholder of Lucid Diagnostics, holding roughly 31 million shares (equity method investment approx. $34 million) and about an 18% ownership stake, with ~25% voting interest.
- +16 more takeaways